prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, .4. Acct/Reg #. ADDENDUM REPORT ". ADDENDUM REPORT NUMBER TWO. BREAST PROGNOSTIC PANEL: Block B2. TEST. REFERENCE RANGES. DNA Analysis by Image: DNA Index: 1.1 (DIPLOID). 0.9-1.1 is Diploid. Her2 Gene Amplification By FISH: UNABLE TO BE DETERMINED. Average copies per cell: Her-2/neu: Chromosome 17: Ratio: > 2.0 Her2/neu. COMMENT: This specimen falled to hybridize successfully with probes specific to Her2/neu gene and chromosome 17 alpha satellite. sequences. Non formalin and ethanol based fixatives as well as age and storage conditions of the specimen may contribute to unsuccessful. FISH analysis. Repeat studies are recommended If additional tissue becomes available from subsequent specimens. Case interpreted by. Notes: Quantitative analysis performed using Chromavision ACIS. The Her2 /neu and CEP17 probes are manufactured by. The Her2/neu gene detection by Fluorescence In Situ Hyondization (FISH) was performed using the LSI Her2/neu DNA probe, specific. for the Her2/neu gene locus 17q11.2-q12 and the CEP1 DNA probe specific for the alpha sateilite DNA sequence at the centromeric. region of chromosome 17 (17p11.1-q11.1). These teste were developed and performance characteristics determined by the. They have not. been cleared or approved by the US Food and Drug Administration. The FDA has determined that such approval or clearance Is. necessary. These tests are used for clinical purposes. They should not be regarded as Investigational or for research. This. laboratory is certified under the Clinical Laboratory Improvement Act (CLIA) of 1988 as qualified to perform high complexity clinical. laboratory testing. ADDENDUM REPORT NUMBER ONE. BREAST PROGNOSTIC PANEL: (Preliminary test results on block B2.). TEST. REFERENCE RANGES. Estrogen Receptor: Positive (95%). 4% is Positive. 2-4% la Borderline. < 2% is Negative. Progesterone Receptor: Negative (0%). > 4% Is Positive. 2-4% is Borderline. for 4/10/11. < 2% Is Negative. KI-67 (MIB1) Proliferation Marker: Low (<10%). > 20% Is High. 10-20% is Borderline. < 10% is Low. These results were interpreted by E. An additional addendum report will follow when DNA and Her-2-neu tests. are completed. These tests were developed and performance characteristics determined by. They have not been cleared or approved by. the US Food and Drug Administration. The FOA has determined that such approval or clearance is not necessary. These tests are used for. clinical purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory. Improvement Act (CLIA) of 1988 as qualified to perform high complexity clinical laboratory testing. DIAGNOSIS. DIAGNOSIS: A,B,C: Left mastectomy with left sentinel lymph node and additional lymph node for diagnosis of breast carcinoma: Tumor Characteristics: 1. Histologic type: Inflitrating lobular carcinomas. 2. Size: 2.5 x 2 x 1.8 cm. 3. Elston modification of Bloom-Richardson grade: a. Architectural Score:3/3. b. Nuclear Score: 2/3. C. Mitotic Score: 1/3. d. Total score: 6/9 - Grade: II. 4. In-situ component: Present. e. Amount: Less then 25%. f. Histologic type: Lobular carcinoma in situ. g. Architectural type: Solld. h. Nuclear grade: II. i. Comedo necrosis: Absent. 5. Margin status for in situ carcinoma: Not transected. 6. Lymphovascular space invasion: No. 7. Skin Involvement: No. 8. Are microcalcifications identified In association with tumor: No. Surgical Margin Status: 1. Is tumor transected: No. 2. Tumor distance to closest margin: 1.6 cm deep margin. Lymph Node Status: 1. Total number of lymph nodes examined: Ten. 2. Total number of lymph nodes containing metastatic carcinoma by gross exam or light microscopy: Sentinel, 1/2; Level 1 and II, 1/8. 3. Size of largest metastasis: 9 mm. 4. Extra-capsular extension of tumor: No. Other: 1. Other significant findings: Fibrocystic change with epithelial hyperplasia and benign calcifications. 2. Block prognostic Indicators will be obtained on paraffin block B2. 3. Correlation Statement with Intra-op consult or frozen section: Frozen section diagnosis sentinel lymph is confirmed by permanent. section malysis. 4. PTNM stäge: T2N1MX. 5. If further required In the future, infiltrating carcinoma is best seen in blocks B2,3,4 and 6. DIAGNOSIS. D. Skin, lip, blopsy: Benign solar lentigo (pigmented actinic keratosis). CLINICAL INFORMATION. CLINICAL HISTORY: Preoperative Diagnosis: Left breast cancer. Postoperative Diagnosis: Symptoms/Radiologic Findings: SPECIMENS: A. Left sentinei lymph node FS. B. Left breast tissue. C. Left lymph nodes. D. Seborrhelc keratosis of lip. SPECIMEN DATA. GROSS DESCRIPTION: A. Container A is labeled A and consists of a tan-yellow firm fatty nodule, 2.0 x 1.0x 1.0 cm in greatest dimension. The specimen is trisected. and entirely submitted for frozen section in one cassette labeled. B. Container B is labeled Ir, B and consists of a 255 gram portion of left breast tissue, 14.0 x 11.0 x 6.0 cm with attached tan-gray ellipse of skin,. 5,0 x 4.2 cm displaying a centrally located flattened nipple, 0.8 cm in greatest dimension. The deep margin is inked and the specimen is sectioned to. reveal predominately tan-yellow lobular adipose tissue intermixed with moderate amounts of tan-gray dense fibrous tissue. A gray-white stellate gritty. mass is noted in the upper outer quadrant and is 2.5 x 2.0x 1.8 cm in greatest dimension. Samples of this mase have been submitted for genomic. studies. This mass is located 2.0 cm from the skin surface and 1.5 cm from the deep margin. No other lesions are grossly noted. The lateral margin. displays a gray-white minute nodule possibly representing lymph node, 0.2 cm. Representative sections submitted in eleven cassettes lá. as follows: nipple-1; stellate mass-2 to 5; deep margin-6; upper inner quadrant-7; upper outer-8; lower inner-9; lower outer-10; lateral. nodule 11. C. Container c is labeled. consists of a tan-yellow lobular mass of adipose tissue, 11.0 x 4.0 x 2.0 cm in greatest dimension. Sectioning. reveals eight tan-yellow firm falty nodules, the largest 1.5 cm. Samples of these nodules submitted in four cassettes labeled. D. Container D is labeled D and consists of a tan-gray granular raised lesion, 0.5 x 0.3 x 0.2 cm. The skin surface displays a mottled dark. brown discoloration. The specimen is inked, serially sectioned and entirely submitted in one cassette labeled 1.

expanded version (tokens=2116) : 
 The breast pathology report provides the following information:

1. Histological classification: Infiltrating lobular carcinoma with a lobular carcinoma in situ component.
2. Subtype: Luminal A.
3. Necrosis: Comedo necrosis is absent.
4. Tumor infiltrating lymphocytes: Not mentioned in the report.
5. Histological grade: Elston modification of Bloom-Richardson grade II, with an architectural score of 3/3, nuclear score of 2/3 and mitotic score of 1/3.
6. Nuclear grade: Grade II.
7. Lymphovascular invasion: No invasion was noted.
8. Calcification: No calcifications were identified in association with the tumor.
9. Receptor status: Estrogen receptor positive (95%), progesterone receptor negative (0%).
10. IHC and ancillary testing results: DNA analysis by Image showed a DNA index of 1.1, indicating a diploid tumor. Her2 gene amplification by FISH was unable to be determined due to the specimen not hybridizing successfully with probes specific to the Her2/neu gene and chromosome 17 alpha satellite sequences.

Other information provided in the report includes:
- The size of the tumor is 2.5 x 2 x 1.8 cm.
- A total of ten lymph nodes were examined, with one sentinel and one level 1/2 lymph node containing metastatic carcinoma detected.
- The report mentions

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2301) : 
 Infiltrating lobular carcinoma with a lobular carcinoma in situ component was found in a 2.5 x 2 x 1.8 cm mass in the left breast. The tumor is Luminal A subtype and has Elston modification of Bloom-Richardson grade II, with an architectural score of 3/3, nuclear score of 2/3 and mitotic score of 1/3. Comedo necrosis is absent and there was no lymphovascular invasion or calcification noted. Estrogen receptors are positive (95%), progesterone receptors are negative (0%). Her2 gene amplification by FISH analysis was unsuccessful due to reasons specified.

